Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Huperzine A

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Huperzine A?

Huperzine A is an investigational drug.

There have been 11 clinical trials for Huperzine A. The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2009.

The most common disease conditions in clinical trials are Alzheimer Disease, Cognition Disorders, and Seizures. The leading clinical trial sponsors are Biscayne Neurotherapeutics, Inc., Baylor College of Medicine, and Spaulding Rehabilitation Hospital.

Recent Clinical Trials for Huperzine A
BIS-001-ER for the Treatment of Adult Focal Impaired Awareness SeizuresBiscayne Neurotherapeutics Australia Pty, Ltd.Phase 1/Phase 2
BIS-001-ER for the Treatment of Adult Focal Impaired Awareness SeizuresBiscayne Neurotherapeutics, Inc.Phase 1/Phase 2
Bioavailability, Safety, and Tolerability of BIS-001 ERMelbourne HealthPhase 1

See all Huperzine A clinical trials

Clinical Trial Summary for Huperzine A

Top disease conditions for Huperzine A
Top clinical trial sponsors for Huperzine A

See all Huperzine A clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.